News
Cancer Genome Project will put San Antonio in research spotlight
South Texas Accelerated Research Therapeutics' Dr. Anthony Tolcher says the Alamo City has an opportunity ...
San Antonio urology professors lead nation in research funding
By James Aldridge, San Antonio Business Journal University of Texas Health Science Center at San Antonio ...
Events
3rd Annual Medical Tourism Research Conference
February 13-15, 2012 Locaton: Omni La Mansion del Rio, 112 College Street, San Antonio, Texas 78205 Featuring: ...Industry Publications
The Mission
The Mission is published by the University of Texas Health Science Center.
UTSA Discovery
UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...
GenSpera Inc. has reached a milestone in the development of its investigational cancer drug.
In a phase 1 clinical study, doctors at the University of Wisconsin Carbone Cancer Center in Madison treated the first patient with GenSpera’s cancer chemotherapeutic agent G-202.
The phase 1 clinical study is designed to treat up to 30 patients with cancers that have progressed even after treatment with other anti-cancer therapies. The study will determine the safety, tolerability and effect the drug has on the human body. Researchers will also study how effective the drug is in treating solid tumors.
G-202 is designed to target the blood vessels in solid tumors in order to destroy the tumor’s blood supply.
San Antonio-based GenSpera is a development stage oncology company.
